Denileukin diftitox: a concise clinical review
2005; Taylor & Francis; Volume: 5; Issue: 1 Linguagem: Inglês
10.1586/14737140.5.1.33
ISSN1744-8328
AutoresJohn Eklund, Timothy M. Kuzel,
Tópico(s)CAR-T cell therapy research
ResumoDenileukin diftitox (DAB389IL-2; Ontak®) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.
Referência(s)